Establishment Labs Holdings Inc. (ESTA)
After hours:
| Previous close | 43.59 |
| Open | 43.14 |
| Bid | 43.85 x 400 |
| Ask | 43.99 x 200 |
| Day's range | 42.93 - 44.46 |
| 52-week range | 16.96 - 73.00 |
| Volume | |
| Avg. volume | 320,927 |
| Market cap | 1.207B |
| Beta (5Y monthly) | 1.22 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Establishment Labs Announces Participation in Two Upcoming Investment Conferences
NEW YORK, May 23, 2024--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced its participation in two upcoming investment conferences.
- Business Wire
Establishment Labs Reports First Quarter 2024 Financial Results
NEW YORK, May 08, 2024--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the first quarter ended March 31, 2024.
- Business Wire
Establishment Labs Notes Presentation of 4-Year Results from Motiva U.S. IDE Study at The Aesthetic Meeting 2024
NEW YORK, May 02, 2024--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, noted the presentation today of an update on the Motiva US IDE Study. The update will include four-year patient follow-up data for primary augmentation subjects. The Medical Director of the Study, Dr. Caroline Glicksman, who is also an Investigator in the Study, will present the result
